396 related articles for article (PubMed ID: 12624517)
21. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer.
Smith AM; Justin T; Michaeli D; Watson SA
Clin Cancer Res; 2000 Dec; 6(12):4719-24. PubMed ID: 11156225
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis.
Bowen JD; Petersdorf SH; Richards TL; Maravilla KR; Dale DC; Price TH; St John TP; Yu AS
Clin Pharmacol Ther; 1998 Sep; 64(3):339-46. PubMed ID: 9757158
[TBL] [Abstract][Full Text] [Related]
23. A first-in-human study of conatumumab in adult patients with advanced solid tumors.
Herbst RS; Kurzrock R; Hong DS; Valdivieso M; Hsu CP; Goyal L; Juan G; Hwang YC; Wong S; Hill JS; Friberg G; LoRusso PM
Clin Cancer Res; 2010 Dec; 16(23):5883-91. PubMed ID: 20947515
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.
Saleh MN; Khazaeli MB; Wheeler RH; Allen L; Tilden AB; Grizzle W; Reisfeld RA; Yu AL; Gillies SD; LoBuglio AF
Hum Antibodies Hybridomas; 1992 Jan; 3(1):19-24. PubMed ID: 1576319
[TBL] [Abstract][Full Text] [Related]
25. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33.
Ritter G; Cohen LS; Williams C; Richards EC; Old LJ; Welt S
Cancer Res; 2001 Sep; 61(18):6851-9. PubMed ID: 11559561
[TBL] [Abstract][Full Text] [Related]
26. Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies.
Dillman RO; Beauregard JC; Halpern SE; Clutter M
J Biol Response Mod; 1986 Feb; 5(1):73-84. PubMed ID: 3514799
[TBL] [Abstract][Full Text] [Related]
27. Toxicities associated with monoclonal antibody infusions in cancer patients.
Dillman RO; Beauregard JC; Jamieson M; Amox D; Halpern SE
Mol Biother; 1988; 1(2):81-5. PubMed ID: 3269251
[TBL] [Abstract][Full Text] [Related]
28. [Incidence of infusion reactions induced by cetuximab chemotherapy].
Maeda T; Tatematsu M; Muro K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
[TBL] [Abstract][Full Text] [Related]
29. Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report.
Verrill H; Goldberg M; Rosenbaum R; Abbott R; Simunovic L; Steplewski Z; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S175-83. PubMed ID: 3527947
[TBL] [Abstract][Full Text] [Related]
30. Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal cancer.
Triozzi PL; Kim JA; Martin EW; Colcher D; Heffelfinger M; Rucker R
Hybridoma; 1997 Apr; 16(2):147-51. PubMed ID: 9145316
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical trial of CO17-1A monoclonal antibody.
Lobuglio AF; Saleh M; Peterson L; Wheeler R; Carrano R; Huster W; Khazaeli MB
Hybridoma; 1986 Jul; 5 Suppl 1():S117-23. PubMed ID: 3488950
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.
Kloft C; Graefe EU; Tanswell P; Scott AM; Hofheinz R; Amelsberg A; Karlsson MO
Invest New Drugs; 2004 Jan; 22(1):39-52. PubMed ID: 14707493
[TBL] [Abstract][Full Text] [Related]
33. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer.
Kim RD; Azad NS; Morse MA; Poplin E; Mahipal A; Tan B; Mavroukakis SA; Fantini M; Tsang KY; Zaki A; Torrealba J; Arlen PM; Beg MS
Clin Cancer Res; 2020 Jul; 26(14):3557-3564. PubMed ID: 32303539
[TBL] [Abstract][Full Text] [Related]
34. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.
Stragliotto G; Vega F; Stasiecki P; Gropp P; Poisson M; Delattre JY
Eur J Cancer; 1996 Apr; 32A(4):636-40. PubMed ID: 8695267
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.
Tanswell P; Garin-Chesa P; Rettig WJ; Welt S; Divgi CR; Casper ES; Finn RD; Larson SM; Old LJ; Scott AM
Br J Clin Pharmacol; 2001 Feb; 51(2):177-80. PubMed ID: 11259992
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.
Narra K; Mullins SR; Lee HO; Strzemkowski-Brun B; Magalong K; Christiansen VJ; McKee PA; Egleston B; Cohen SJ; Weiner LM; Meropol NJ; Cheng JD
Cancer Biol Ther; 2007 Nov; 6(11):1691-9. PubMed ID: 18032930
[TBL] [Abstract][Full Text] [Related]
37. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
Morris MJ; Pandit-Taskar N; Divgi CR; Bender S; O'Donoghue JA; Nacca A; Smith-Jones P; Schwartz L; Slovin S; Finn R; Larson S; Scher HI
Clin Cancer Res; 2007 May; 13(9):2707-13. PubMed ID: 17473203
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of cyclosporin A in the treatment of refractory metastatic colorectal cancer.
Murren JR; Ganpule S; Sarris A; Durivage H; Davis C; Makuch R; Handschumacher RE; Marsh JC
Am J Clin Oncol; 1991 Jun; 14(3):208-10. PubMed ID: 2031507
[TBL] [Abstract][Full Text] [Related]
39. [Monoclonal antibodies in the therapy of non-resectable pancreatic cancers. Initial experiences].
Muhrer KH; Büchler M; Lucks A; Süss D; Klapdor R; Schulz G
Chirurg; 1988 May; 59(5):328-34. PubMed ID: 3396446
[TBL] [Abstract][Full Text] [Related]
40. The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma.
Mellstedt H; Frödin JE; Ragnhammar P; Masucci G; Shetye J; Christensson B; Biberfeld P; Makower J; Pihlstedt P; Cedermark B
Med Oncol Tumor Pharmacother; 1989; 6(1):99-107. PubMed ID: 2786122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
